beta 1 Adrenergic Receptor/ADRB1/β₁-AR CRISPR/Cas9 KO Plasmid (h): sc-400660

Overview

ADRB1 encodes the human beta 1 adrenergic receptor (β1-AR), a G protein–coupled receptor that primarily couples to Gs to stimulate adenylyl cyclase, elevate cAMP, and activate PKA-dependent phosphorylation programs. β1-AR signaling regulates cardiac chronotropy and inotropy, influences calcium handling and contractile machinery, and integrates with MAPK/ERK and GRK–β-arrestin pathways that shape receptor desensitization and downstream transcriptional responses. In addition to cardiomyocytes, ADRB1 activity modulates metabolic and stress-response signaling in multiple tissues through sympathetic catecholamine input. Genetic and functional variation in ADRB1 and dysregulated β1-AR signaling have been linked to cardiovascular phenotypes and altered responses in models of cardiac remodeling and adrenergic overstimulation.

beta 1 Adrenergic Receptor/ADRB1/β1-AR CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADRB1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADRB1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADRB1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish beta 1 Adrenergic Receptor/ADRB1/β1-AR protein expression.

This CRISPR knockout system enables efficient generation of ADRB1-deficient cell models for investigation of beta 1 Adrenergic Receptor/ADRB1/β1-AR signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting ADRB1 exon(s) critical for beta 1 Adrenergic Receptor/ADRB1/β1-AR function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple ADRB1 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by beta 1 Adrenergic Receptor/ADRB1/β1-AR CRISPR/Cas9 KO Plasmid (h) and beta 1 Adrenergic Receptor/ADRB1/β1-AR CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ADRB1 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by beta 1 Adrenergic Receptor/ADRB1/β1-AR HDR Plasmid (h) and beta 1 Adrenergic Receptor/ADRB1/β1-AR HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ADRB1 homology arms to support homology-directed repair at defined ADRB1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.